Press Releases
Search
-
12 Apr 2022
Antimicrobial Resistance
Specific Diagnostics acquisition
bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures.
-
11 Apr 2022
Financial Information
First-Quarter 2022 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2022.
-
18 Mar 2022
Business & Solutions
bioMérieux receives FDA 510(k) clearance for its VITEK® MS PRIME new MALDI-TOF mass spectrometry identification system
bioMérieux, a world leader in the field of in vitro diagnostics, announces that VITEK® MS PRIME, its new MALDI-TOF mass spectrometry identification system, has received 510(k) clearance from the U.S. ...
-
02 Mar 2022
Financial Information
bioMérieux – 2021 Financial Results
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on March 1 under the chairmanship of Alexandre Mérieux and approved the audited consolidated financial st...
-
17 Feb 2022
Business & Solutions
MYACUTECASE™, a free mobile application by bioMérieux to support clinicians in decision-making and monitoring of patients using emergency and critical care diagnostics
bioMérieux, a world leader in the field of in vitro diagnostics, launches MYACUTECASETM. This mobile application, the first of a kind developed by bioMérieux, is an aid in the interpretation of VIDAS®...
-
06 Jan 2022
Partnerships
French multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance
The ARPEGE project aims to develop a set of solutions to strengthen the ability of healthcare institutions to fight antibiotic resistance. The consortium, led by Antabio, has been awarded close to €9 ...